Literature DB >> 23617349

Second surgery for recurrent glioblastoma: advantages and pitfalls.

Alba A Brandes1, Marco Bartolotti, Enrico Franceschi.   

Abstract

Deciding upon the therapeutic approach for patients with recurrent glioblastoma is a challenge. Although second surgery may provide effective palliation, it has yet to be established whether it prolongs survival and/or improves quality of life; nor have data been reported in literature to demonstrate that repeat surgery is indicated for patients with recurrence. The few studies investigating this issue are retrospective and have been conducted on small series, and their data sets are not homogeneous. The aim of the present study was, therefore, to analyze predictors of outcome in patients with recurrent glioblastoma and to make a critical of review of data in literature with a view to comparing the effect on outcome of second surgery against well-known prognostic determinants.

Entities:  

Mesh:

Year:  2013        PMID: 23617349     DOI: 10.1586/era.13.32

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  12 in total

1.  Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma.

Authors:  Michael Back; Cecelia E Gzell; Marina Kastelan; Linxin Guo; Helen R Wheeler
Journal:  Neurooncol Pract       Date:  2014-12-15

2.  Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome.

Authors:  Cecilia L Dalle Ore; Ankush Chandra; Jonathan Rick; Darryl Lau; Maryam Shahin; Alan T Nguyen; Michael McDermott; Mitchel S Berger; Manish K Aghi
Journal:  Neurosurgery       Date:  2019-12-01       Impact factor: 4.654

Review 3.  Glioblastoma: Overview of Disease and Treatment.

Authors:  Mary Elizabeth Davis
Journal:  Clin J Oncol Nurs       Date:  2016-10-01       Impact factor: 1.027

Review 4.  Recurrent malignant gliomas.

Authors:  John P Kirkpatrick; John H Sampson
Journal:  Semin Radiat Oncol       Date:  2014-10       Impact factor: 5.934

5.  Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience.

Authors:  Shaakir Hasan; Eda Chen; Rachelle Lanciano; Jun Yang; Alex Hanlon; John Lamond; Stephen Arrigo; William Ding; Michael Mikhail; Arezoo Ghaneie; Luther Brady
Journal:  Front Oncol       Date:  2015-05-15       Impact factor: 6.244

Review 6.  Treating malignant glioma in Chinese patients: update on temozolomide.

Authors:  Liang Chang; Jun Su; Xiuzhi Jia; Huan Ren
Journal:  Onco Targets Ther       Date:  2014-02-12       Impact factor: 4.147

7.  Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.

Authors:  Nicholas Brown; Catherine McBain; Stephen Nash; Kirsten Hopkins; Paul Sanghera; Frank Saran; Mark Phillips; Fiona Dungey; Laura Clifton-Hadley; Katharina Wanek; Daniel Krell; Sarah Jeffries; Iftekhar Khan; Paul Smith; Paul Mulholland
Journal:  PLoS One       Date:  2016-05-27       Impact factor: 3.240

8.  CyberKnife for Recurrent Malignant Gliomas: A Systematic Review and Meta-Analysis.

Authors:  Lucio De Maria; Lodovico Terzi di Bergamo; Alfredo Conti; Kazuhiko Hayashi; Valentina Pinzi; Taro Murai; Rachelle Lanciano; Sigita Burneikiene; Michela Buglione di Monale; Stefano Maria Magrini; Marco Maria Fontanella
Journal:  Front Oncol       Date:  2021-03-29       Impact factor: 6.244

Review 9.  Current FDA-Approved Therapies for High-Grade Malignant Gliomas.

Authors:  Jacob P Fisher; David C Adamson
Journal:  Biomedicines       Date:  2021-03-22

10.  Biopsy vs. extensive resection for first recurrence of glioblastoma: is a prospective clinical trial warranted?

Authors:  Christopher Dardis; Lynn Ashby; William Shapiro; Nader Sanai
Journal:  BMC Res Notes       Date:  2015-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.